Zai Lab Q4 Earnings Call Highlights

Amado said Zai anticipates a potential accelerated approval submission in 2027 and “a first global approval in 2028.” He also pointed to clinical activity in patients with brain metastases, including an 80% objective response rate in 10 patients with untreated brain metastases, and said the company plans to present additional data in coming months.President and Head of Global R&D Dr. Rafael Amado detailed progress for zoci (a DLL3-targeting antibody-drug conjugate), which the company is advancing in small c ...